Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
NeuroTransmitter
Erschienen in: NeuroTransmitter 9/2022

08.09.2022 | Vorhofflimmern | Zertifizierte Fortbildung

Direkte orale Antikoagulanzien

Pharmakologische Eigenschaften mit Praxisrelevanz

verfasst von: Dr. med. Sonja Faust

Erschienen in: NeuroTransmitter | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Auszug

Die Indikationen für eine Antikoagulation haben sich in den letzten Jahrzehnten stark ausgeweitet. Neben Heparinen und Vitamin-K-Antagonisten wurden auch direkte orale Antikoagulanzien (DOAK) entwickelt, die direkt die enzymatische Aktivität von Thrombin (Faktor IIa) und Stuart-Prower-Faktor (Faktor Xa) und damit unter anderem prokoagulatorische Prozesse an entscheidender Stelle hemmen. Nur die Kenntnis der spezifischen Eigenschaften, Risiken und Vorteile dieser Präparate, erlaubt deren korrekten Einsatz. Für Neurologen und Nervenärzte sind vor allem die Indikationen im Bereich des Vorhofflimmerns als Primär- und Sekundärprävention ischämischer Hirninfarkte und der Mitbehandlung von Patienten mit venösen thromboembolischen Ereignissen relevant. …
Literatur
1.
Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353(10):1028-40
2.
Turpie AGG. New oral anticoagulants in atrial fibrillation. European heart journal. 2008;29(2):155-65
3.
Berry CN et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thrombosis and haemostasis. 1994;72(3):381-6
4.
Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation. 1994;90(3):1522-36
5.
Weitz JI et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86(2):385-91
6.
Laux V et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thrombosis and haemostasis. 2009;102(5):892-9
7.
Roehrig S et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- 4-(3-oxomorpholin-4-yl)phenyl-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem. 2005;48(19):5900-8
8.
Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thrombosis research. 2011;127(6):497-504
9.
Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-23
10.
Trujillo-Santos J et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thrombosis and haemostasis. 2017;117(2):382-9
11.
Arbel R et al. Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. The American journal of medicine. 2019;132(7):847-55.e3
12.
Ha JT et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Annals of internal medicine. 2019;171(3):181-9
13.
Cheung CYSet al. Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes. The Annals of pharmacotherapy. 2021;55(6):711-22
14.
Chatterjee S et al. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clinic proceedings. 2014;89(7):896-907
15.
Chai-Adisaksopha C et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. Journal of thrombosis and haemostasis: JTH. 2015;13(11):2012-20
16.
Mannucci PM. Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. European Journal of Internal Medicine. 2013;24(4):285-7
17.
Lutsey PLet al. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation. JAMA internal medicine. 2020;180(2):245-53
18.
Hirsh J et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):141S-59S
19.
Eitzman DTet al. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation. 1994;89(4):1523-9
20.
Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. Journal of the American College of Cardiology. 2018;71(19):2162-75
21.
Hauel NH et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. Journal of medicinal chemistry. 2002;45(9):1757-66
22.
23.
van Ryn J et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and haemostasis. 2010;103(6):1116-27
24.
Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clinical pharmacokinetics. 2010;49(4):259-68
25.
Blech S et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug metabolism and disposition: the biological fate of chemicals. 2008;36(2):386-99
26.
27.
Martin KA et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021 Aug;19(8):1874-82
28.
Reilly PA et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). Journal of the American College of Cardiology. 2014;63(4):321-8
29.
Powell JR. Are new oral anticoagulant dosing recommendations optimal for all patients? JAMA. 2015;313(10):1013-4
30.
Chan N et al. Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? American heart journal. 2018;199(25 Pt A):59-67
31.
Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ (Clinical research ed.). 2014;349g4517
32.
Rao RB. Regarding the effect of dabigatran plasma concentrations. Journal of the American College of Cardiology. 2014;63(25 Pt A):2885.
33.
van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. The American journal of medicine. 2012;125(4):417-20
34.
Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272-4
35.
Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thrombosis and haemostasis. 2013;110(2):205-12
36.
Schulman Set al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. Journal of thrombosis and haemostasis: JTH. 2013;11(7):1295-9
37.
Cheng JWM, Vu H. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. Clinical therapeutics. 2012;34(4):766-87
38.
Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51
39.
Bytzer P et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2013;11(3):246-52.e1-5
40.
Dawwas GK et al. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Annals of internal medicine. 2022;175(1):20-8
41.
Ingason AB et al. Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score-Weighted Study Ann Intern Med. 2021;174(11):1493-502
42.
Gosselin RC et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thrombosis and haemostasis. 2018;118(3):437-50
43.
Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012;72(13):1739-53
44.
45.
KBV. DOAK Eigenschaften und Therapiewechsel [Internet].
46.
Granger CB et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American heart journal. 2015;169(1):25-30
47.
Cairns JA et al. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. American heart journal. 2015;169(1):1-3
Metadaten
Titel
Direkte orale Antikoagulanzien
Pharmakologische Eigenschaften mit Praxisrelevanz
verfasst von
Dr. med. Sonja Faust
Publikationsdatum
08.09.2022
Verlag
Springer Medizin
Erschienen in
NeuroTransmitter / Ausgabe 9/2022
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI
https://doi.org/10.1007/s15016-022-9555-9

Weitere Artikel der Ausgabe 9/2022

NeuroTransmitter 9/2022 Zur Ausgabe

Journal

Hochsitze - jenseits der Norm

Aus den Verbänden

Erfolgreich auch in Zeiten von COVID-19

Pharmaforum

Mit inhalativem Levodopa gegen Off-Episoden

Pharmaforum

Multiple Sklerose: Zeitfenster zu Krankheitsbeginn nicht ungenutzt verstreichen lassen

Aus den Verbänden

Stärkung der Online-Auftritte unserer Landesverbände im Fokus

Pharmaforum

PPMS und SPMS: Behinderungsprogression verringern und kognitive Leistungsfähigkeit erhalten